Nuvalent, Inc. 4

Nuvalent CFO Alexandra Balcom had all common shares, RSUs, PSUs, and stock options cancelled or cashed out at $124.00 per share (less option exercise prices) in connection with GSK’s acquisition of Nuvalent.

On July 15, 2026, in connection with the closing of GSK’s acquisition of Nuvalent, Inc., CFO Alexandra Balcom’s 44,433 shares of Nuvalent Class A Common Stock (including shares underlying equity awards that became deliverable) were cashed out at $124.00 per share pursuant to the tender offer and merger, her 41,100 time-based RSUs and 14,350 performance stock units were cancelled for cash at the same offer price, and all of her outstanding stock options (covering an aggregate 329,432 shares across multiple strike prices from $1.08 to $106.82) were cancelled and converted into cash equal to the intrinsic value (offer price minus exercise price) for each grant. These transactions are mechanical changes of form arising from the merger consideration structure, leaving Balcom with no remaining equity ownership in Nuvalent, which became a wholly owned subsidiary of GlaxoSmithKline LLC.

Filing Facts

CIK

1861560

Ticker

NUVL

Form

4

Source Type

fda

Accession

0001193125-26-305094

Alert Tier

6